k

Prostaglandins (PG)

  • The structural differences between prostaglandins account for their different biological activities. A given prostaglandin may have different and even opposite effects in different tissues in some cases. The ability of the same prostaglandin to stimulate a reaction in one tissue and inhibit the same reaction in another tissue is determined by the type of receptor to which the prostaglandin binds. They act as autocrine or paracrine factors with their target cells present in the immediate vicinity of the site of their secretion. Prostaglandins differ from endocrine hormones in that they are not produced at a specific site but in many places throughout the human body.
  • Prostaglandins are powerful, locally-acting vasodilators and inhibit the aggregation of blood platelets. Through their role in vasodilation, prostaglandins are also involved in inflammation. They are synthesized in the walls of blood vessels and serve the physiological function of preventing needless clot formation, as well as regulating the contraction of smooth muscle tissue.
    • Nelson RF (2005). An introduction to behavioral endocrinology (3rd ed.). Sunderland, Mass: Sinauer Associates. p. 100. ISBN 0-87893-617-3. 
  • Conversely, thromboxanes (produced by platelet cells) are vasoconstrictors and facilitate platelet aggregation. Their name comes from their role in clot formation (thrombosis).
  • Specific prostaglandins are named with a letter (which indicates the type of ring structure) followed by a number (which indicates the number of double bonds in the hydrocarbon structure). For example, prostaglandin E1 is abbreviated PGE1, and prostaglandin I2 is abbreviated PGI2.

History and name

Biochemistry

Biosynthesis of eicosanoids

Biosynthesis

Arachidonic acid is created from diacylglycerol via phospholipase-A2, then brought to either the cyclooxygenase pathway or the lipoxygenase pathway. The cyclooxygenase pathway produces thromboxaneprostacyclin and prostaglandin D, E and F. Alternatively, the lipoxygenase enzyme pathway is active in leukocytes and in macrophages and synthesizes leukotrienes.

Release of prostaglandins from the cell

Prostaglandins were originally believed to leave the cells via passive diffusion because of their high lipophilicity. The discovery of the prostaglandin transporter (PGT, SLCO2A1), which mediates the cellular uptake of prostaglandin, demonstrated that diffusion alone cannot explain the penetration of prostaglandin through the cellular membrane. The release of prostaglandin has now also been shown to be mediated by a specific transporter, namely the multidrug resistance protein 4 (MRP4, ABCC4), a member of the ATP-binding cassette transporter superfamily. Whether MRP4 is the only transporter releasing prostaglandins from the cells is still unclear.

Cyclooxygenases

Prostaglandins are produced following the sequential oxygenation of arachidonic acid, DGLA or EPA by cyclooxygenases (COX-1 and COX-2) and terminal prostaglandin synthases. The classic dogma is as follows:

  • COX-1 is responsible for the baseline levels of prostaglandins.
  • COX-2 produces prostaglandins through stimulation.

However, while COX-1 and COX-2 are both located in the blood vesselsstomach and the kidneys, prostaglandin levels are increased by COX-2 in scenarios of inflammation and growth.

Prostaglandin E synthase

Other terminal prostaglandin synthases

  • Terminal prostaglandin synthases have been identified that are responsible for the formation of other prostaglandins. For example, hematopoietic and lipocalin prostaglandin D synthases (hPGDS and lPGDS) are responsible for the formation of PGD2 from PGH2. Similarly, prostacyclin (PGI2) synthase (PGIS) converts PGH2 into PGI2. A thromboxane synthase (TxAS) has also been identified. Prostaglandin-F synthase (PGFS) catalyzes the formation of 9α,11β-PGF2α,β from PGD2 and PGF from PGH2 in the presence of NADPH. This enzyme has recently been crystallized in complex with PGD2
    • Komoto J, Yamada T, Watanabe K, Takusagawa F (March 2004). “Crystal structure of human prostaglandin F synthase (AKR1C3)”. Biochemistry43 (8): 2188–98. doi:10.1021/bi036046xPMID 14979715. 
  • and bimatoprost (a synthetic analogue of PGF).
    • Komoto J, Yamada T, Watanabe K, Woodward DF, Takusagawa F (February 2006). “Prostaglandin F2alpha formation from prostaglandin H2 by prostaglandin F synthase (PGFS): crystal structure of PGFS containing bimatoprost”. Biochemistry45 (7): 1987–96. doi:10.1021/bi051861tPMID 16475787. 

Functions

There are currently ten known prostaglandin receptors on various cell types. Prostaglandins ligate a sub-family of cell surface seven-transmembrane receptors, G-protein-coupled receptors. These receptors are termed DP1-2, EP1-4, FP, IP1-2, and TP, corresponding to the receptor that ligates the corresponding prostaglandin (e.g., DP1-2 receptors bind to PGD2).

The diversity of receptors means that prostaglandins act on an array of cells and have a wide variety of effects such as:

Types

TypeReceptorReceptor typeFunction
PGI2IPGsvasodilation inhibit platelet aggregation bronchodilation
PGD2PTGDR (DP1) and CRTH2 (DP2)GPCRproduced by mast cells; recruits Th2 cells, eosinophils, and basophils In mammalian organs, large amounts of PGD2 are found only in the brain and in mast cells Critical to development of allergic diseases such as asthma
PGE2EP1Gqbronchoconstriction GI tract smooth muscle contraction
EP2Gsbronchodilation GI tract 
smooth muscle relaxation
vasodilation
EP3Gi↓ gastric acid secretion
↑ gastric mucus secretion
uterus contraction (when pregnant)
GI tract smooth muscle contraction lipolysis inhibition
↑ autonomic neurotransmitters[1]
↑ platelet response to their agonists[2] and
↑ atherothrombosis in vivo[3]
Unspecifiedhyperalgesia[1] pyrogenic
PGFFPGquterus contraction bronchoconstriction urinary bladder contractions[4] vasoconstriction in cerebral circulation[5]
  1. Rang HP (2003). Pharmacology (5th ed.). Edinburgh: Churchill Livingstone. p. 234. ISBN 0-443-07145-4.
  2. Fabre JE, Nguyen M, Athirakul K, Coggins K, McNeish JD, Austin S, Parise LK, FitzGerald GA, Coffman TM, Koller BH (March 2001). “Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation”. The Journal of Clinical Investigation. 107 (5): 603–10. doi:10.1172/JCI10881PMC 199422PMID 11238561.
  3. Gross S, Tilly P, Hentsch D, Vonesch JL, Fabre JE (February 2007). “Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors”. The Journal of Experimental Medicine. 204 (2): 311–20. doi:10.1084/jem.20061617PMC 2118736PMID 17242161.
  4. Stromberga, Zane; Chess-Williams, Russ; Moro, Christian (23 June 2020). “Prostaglandin E2 and F2alpha Modulate Urinary Bladder Urothelium, Lamina Propria and Detrusor Contractility via the FP Receptor”. Frontiers in Physiology. 11: 705. doi:10.3389/fphys.2020.00705PMC 7344237PMID 32714206.
  5. Joshi, Shailendra; Ornstein, Eugene; Young, William L. (2010). “Cerebral and Spinal Cord Blood Flow”. Cottrell and Young’s Neuroanesthesia. pp. 17–59. doi:10.1016/B978-0-323-05908-4.10007-7ISBN 9780323059084.

Role in pharmacology

Inhibition

See also: Prostaglandin antagonist and Mechanism of action of aspirin

Examples of prostaglandin antagonists are:

Clinical uses

Synthetic prostaglandins are used:

Prostaglandin stimulants

  • Cold exposure and IUDs may increase prostaglandin production.
    • Mary Anne Koda-Kimble (2007). Handbook of Applied Therapeutics (8th ed.). Lippincott Williams & Wilkins. p. 1104. ISBN 9780781790260.

See also

  • Prostamides, a chemically related class of physiologically active substances

External links

Hormones
Eicosanoids
Uterotonics/labor inducers/oxytocics (G02A)
Drugs for peptic ulcer and GERD/GORD (A02B)
Drugs used for glaucoma preparations and miosis (S01E)
Urologicals, including antispasmodics (G04B)
Prostanoid signaling modulators

Categories

From Wikipedia where this page was last updated July 4, 2022

Post a Comment

Your email address will not be published. Required fields are marked *